Richard Paul Baum

11PUBLICATIONS
54CO-AUTHORS
Pharmaceutical delivery technologiesProfessional ethicsGene and molecular therapyRadiation therapyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 27, 2025
Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Elisabetta Perrone, Maria Lucia Calcagni, Lucia Leccisotti

|May 30, 2025
Correction to: Guiding principles on the education and practice of theranostics.

Thomas N B Pascual, Diana Paez, Andrei Iagaru

|May 05, 2025
Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.

Jingjing Zhang, Deling Li, Mengqi Shi

|Feb 13, 2025
Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders.

Masha Maharaj, Elisabetta Perrone, Ralph M Wirtz

|Feb 13, 2025
Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.

Elisabetta Perrone, Alessandro Giordano, Maria Lucia Calcagni

|May 11, 2024
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with 177Lu/225AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas.

Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant

Pageof 2

Frequent Collaborators

4 joint publications

Elisabetta Perrone

3 joint publications

Andrew M Scott

3 joint publications

John O Prior

3 joint publications

Aleksandr Eismant